FDA Outlines 'Anticipated Details' of New Oversight Approach for Laboratory Developed Tests
September 22, 2014
Laboratory Developed Tests (LDTs) are tests that are intended for clinical use and designed, manufactured and used within a single laboratory. On July 31, 2014, the federal Food and Drug Administration (FDA) provided advance notice to Congress (as required by statute) of its intent to issue draft guidance for the regulatory oversight of LDTs, after its longstanding approach of “enforcement discretion” for these tests.
This article, written by a team of Foley lawyers from the health care, intellectual property, and FDA practices, originally was published in the BNA Medical Devices Law & Industry Report, and discusses the FDA’s new and significantly different approach to the oversight of LDTs. Continue reading the full article.
Disclaimer
This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.
Author(s)
Related Insights
June 25, 2025
Manufacturing Industry Advisor
Mexico Imposes New Export Notice Requirement for 5 Tariff Lines Covering Certain Mechanical and Electric Machinery and Their Parts
After being postponed twice, effective August 11, 2025, Mexico will require an “Automatic” Export Notice prerequisite (Export Notice,…
June 25, 2025
Health Care Law Today
AI Contracts in Health Care: Avoiding the Data Dumpster Fire
For AI companies in the health care space, data is everything. It fuels model performance, drives product differentiation, and can make…
June 25, 2025
Innovative Technology Insights
AI Contracts in Health Care: Avoiding the Data Dumpster Fire
For AI companies in the health care space, data is everything. It fuels model performance, drives product differentiation, and can make…